Blackbaud (BLKB) Q3 2025 Earnings Transcript

Bausch + Lomb reported Q3 revenue of $1.281 billion, up 6% constant currency, with adjusted EBITDA rising 7% to $243 million and margin improving 400 bps sequentially to 19%. Management raised full-year adjusted EBITDA guidance to $870 million-$910 million from $860 million-$910 million and reaffirmed revenue guidance of $5.05 billion-$5.15 billion. Growth was led by Miebo ($84 million, up 71% y/y), Vision Care (+6%), and a surgical recovery as enVista sales reached 82% of pre-recall levels.

Analysis

The key signal here is not just a clean beat; it is that BLCO is exiting the “launch burn” phase and entering a margin-reset phase while still posting mid-single-digit top-line growth. That combination matters because the market has typically valued this name as a levered, execution-fragile turnaround; a sustained step-down in SG&A with R&D still rising implies operating leverage can expand even without heroic revenue assumptions. The second-order effect is that the company’s internal capital intensity is falling at the same time its cash conversion is improving, which should compress the equity risk premium if management proves the new framework is durable through year-end.

The most important competitive read-through is that the dry-eye franchise appears to be turning a new entrant into a category-expansion catalyst rather than a share-loss event. If combined therapy becomes the default behavior, the winner is the company with the broadest field force, payer access, and complementary mechanisms — not necessarily the best single product — which favors BLCO’s portfolio architecture. The surgical rebound is equally important because a recall-driven rebound typically has more air left than consensus expects; once consignment normalizes and surgeon trust is restored, the follow-through can extend for several quarters rather than one.

The main risk is that the current margin inflection is partly mix- and recovery-driven, so investors may be over-extrapolating Q3 into 2026 before the Investor Day details. Tariff mitigation is being treated as solved, but the company is still exposed to policy volatility and China consumer softness; either could pressure gross margin or growth if macro weakens. The contrarian setup is that the stock may be under-owned because investors focus on leverage and legacy execution issues, while missing that the business is becoming more self-funding exactly as management starts to re-rate the portfolio toward higher-ROIC growth.

Key Decisions for Investors

• Long BLCO into the Nov. 13 Investor Day with a 4-8 week horizon; thesis is multiple expansion on evidence that SG&A leverage and cash conversion are sustainable. Use a disciplined stop if management fails to quantify durable margin expansion or if gross margin guidance is cut.
• Pair trade: long BLCO / short a higher-quality medtech with less operating leverage over the next 2-3 months; BLCO has more room for estimate revisions if the turnaround narrative sticks, while downside is capped by improving cash flow.
• Buy BLCO Jan-2026 upside calls or call spread rather than common ahead of Investor Day; this limits risk to the execution reveal while preserving convexity if management articulates a credible 2026-2027 margin path.
• Trim or avoid adding exposure if the stock pops sharply before Investor Day; the best entry is on any post-event disappointment that is about disclosure format rather than fundamentals.
• For more conservative accounts, hold BLCO as a tactical long only if surgical recovery and pharma coverage metrics hold through Q4 prints; if either stalls, the equity can re-rate lower quickly because the deleveraging story depends on EBITDA continuity.